Deep Dive: The Evolving GLP-1 Class Overview

Published Date: 15 Jul 2026

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Read Full News

Latest News

Recognizing the Manifestations and Multidimensional Impacts of Sjögren's Disease

Recognizing the Manifestations and Multidimensional Impacts of Sjögren's Disease

Exploring Underlying Pathogenesis in Sjögren's Disease and a Rapidly Expanding Therapeutic Landscape

Exploring Underlying Pathogenesis in Sjögren's Disease and a Rapidly Expanding Therapeutic Landscape

IgA Nephropathy: From Clinical Suspicion to Definitive Diagnosis

IgA Nephropathy: From Clinical Suspicion to Definitive Diagnosis

New and Emerging Therapies in IgA Nephropathy: Latest Data and Clinical Implications

New and Emerging Therapies in IgA Nephropathy: Latest Data and Clinical Implications

Navigating New Guidelines in IgA Nephropathy

Navigating New Guidelines in IgA Nephropathy

Advances in Post-Kidney Transplant Immunosuppression: Applying the Latest CNI-Sparing Strategies to Optimize Long-Term Outcomes

Advances in Post-Kidney Transplant Immunosuppression: Applying the Latest CNI-Sparing Strategies to Optimize Long-Term Outcomes

Todays Updates

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

Todays Updates

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

Latest News

Recognizing the Manifestations and Multidimensional Impacts of Sjögren's Disease

Exploring Underlying Pathogenesis in Sjögren's Disease and a Rapidly Expanding Therapeutic Landscape

IgA Nephropathy: From Clinical Suspicion to Definitive Diagnosis

New and Emerging Therapies in IgA Nephropathy: Latest Data and Clinical Implications

Navigating New Guidelines in IgA Nephropathy

Advances in Post-Kidney Transplant Immunosuppression: Applying the Latest CNI-Sparing Strategies to Optimize Long-Term Outcomes

News All Time

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Navigating New Guidelines in IgA Nephropathy

FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

CAR T-Cell Therapy Enabled Kidney Transplant in Highly Sensitized Patients

Strategy offers hope for hard-to-match patients

Trial Dims Prospects for Rivaroxaban's Cardiovascular Protection in Advanced CKD

Trial finds risk, but no benefit, with blood thinner

When Should Our Patients With Diabetes Eat?

Meal timing may be an underused tool

Measured GFR in Line With eGFR for Predicting CKD Outcomes

Combining creatinine and cystitis C offered best accuracy for estimated calculations

B-Cell Depleter Nabs Phase III Win in Autoimmune Kidney Disease

Obinutuzumab tops immunosuppressant tacrolimus for membranous nephropathy remissions

Video: Police Tussle With Diabetes Experts at ADA Meeting

Researchers told they could no longer attend the annual scientific sessions

Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide

But its key advantage is in its weight reduction abilities
HTTP error: 503HTTP error: 503

Monthly GLP-1 for Obesity Promising as More Manageable Alternative

Less frequent dosing could support better long-term adherence, says researcher
HTTP error: 503HTTP error: 503

Rewriting What We Know About Kidney Transplant Rejection

Rewriting What We Know About Kidney Transplant Rejection

Recommended News For You

Study Supports More Inclusive Clinical Trials With Broader Eligibility Criteria

'Sleep ALL night' program helps children with leukemia sleep better during treatment

Analysis of projected cancer rates in Canada by 2024.

Alarm Over Pharma-China Link; Taking Screening to the People; Agriculture and Cancer

Simpler Screening Criteria Could Catch More Lung Cancers

La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

Recommended Articles For You

Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense 

Precision to Personalization: Expanding Genetic Testing and Counseling in Oncology 

Spatial Mapping of Tumor Cell States: Integrating Biology, Technology, and Clinical Practice 

The Essential Roadmap for Nutritional Excellence in Head and Neck Cancer Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chromatin organization linked to p53 tumor suppression mechanism

2.

Despite Medicare Coverage, Cancer Genomic Testing Still Low

3.

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

4.

New protein target discovered for childhood medulloblastomas

5.

CAR T-Cell Therapy for Kidney Cancer Builds on Efficacy Record

1.

Late Effects of Immunotherapy in Chronic Melanoma Survivorship with Repurposed Drugs

2.

Public Health Through Cancer Survivorship Infrastructure at the Community Level

3.

Symptoms and Causes of Phlegmasia Cerulea Dolens: A Comprehensive Guide 

4.

Coagulation Factor Consumption During Severe Inflammation: Mechanisms, Clinical Implications, and Advances

5.

Understanding Iron Saturation Levels in Your Blood 

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

2.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

3.

Immunotherapy: A New Era in Cancer Treatment

4.

Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men

5.

Diagnosis and Management in Hematology

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot